Literature DB >> 24939945

Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis.

David F Hutt1, Anne-Marie Quigley2, Joanne Page2, Margaret L Hall2, Maria Burniston2, Dorothea Gopaul1, Thirusha Lane1, Carol J Whelan1, Helen J Lachmann1, Julian D Gillmore1, Philip N Hawkins1, Ashutosh D Wechalekar3.   

Abstract

AIMS: Technetium-99m-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid ((99m)Tc-DPD) is a sensitive method for imaging cardiac transthyretin (ATTR) amyloid. We report utility and limitations of (99m)Tc-DPD scintigraphy in 321 patients with suspected cardiac amyloidosis. METHODS AND
RESULTS: The cohort included wild-type ATTR (ATTRwt) amyloidosis in 94 (29%), ATTR-Val122Ile amyloidosis in 38 (12%), hereditary ATTR (ATTRmt) amyloidosis in 46 (14%), primary light-chain (AL) amyloidosis in 44 (14%), secondary (AA) amyloidosis in three (1%), other hereditary amyloidosis types in nine (3%), undetermined types in two (0.5%), and 85 (26.5%) patients in whom systemic amyloidosis was ultimately excluded. All 158 patients with ATTR amyloidosis with clinical cardiac involvement had cardiac (99m)Tc-DPD uptake, with median Grade 2 intensity. Thirteen further ATTR amyloidosis patients without clinical evidence of cardiac involvement also demonstrated (99m)Tc-DPD cardiac uptake. Eighteen of 35 (51%) AL patients with cardiac involvement had (99m)Tc-DPD cardiac uptake (median Grade 1 intensity). SPECT imaging indicates that the apparent reciprocal reduction in bone uptake is due to masking of bone uptake by extensive soft-tissue uptake in ATTR amyloidosis, especially ATTRwt, and ATTR-Val122Ile types.
CONCLUSION: (99m)Tc-DPD scintigraphy is a highly sensitive technique for imaging cardiac ATTR amyloidosis and is an important investigation in the diagnostic pathway of patients with cardiac amyloidosis. It is not specific for ATTR in isolation but must be interpreted in a broad clinical context to avoid dangerous diagnostic errors. Diffuse skeletal muscle uptake identifies muscle as a hitherto unrecognized site that merits investigation as a target organ in ATTR amyloidosis. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  99mTc DPD scintigraphy; ATTR; Cardiac amyloid; Soft tissue; Transthyretin

Mesh:

Substances:

Year:  2014        PMID: 24939945     DOI: 10.1093/ehjci/jeu107

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  52 in total

1.  Role of imaging in cardiac amyloidosis: An ongoing challenge.

Authors:  Ashutosh D Wechalekar
Journal:  J Nucl Cardiol       Date:  2015-11-05       Impact factor: 5.952

2.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.

Authors:  Sharmila Dorbala; Yukio Ando; Sabahat Bokhari; Angela Dispenzieri; Rodney H Falk; Victor A Ferrari; Marianna Fontana; Olivier Gheysens; Julian D Gillmore; Andor W J M Glaudemans; Mazen A Hanna; Bouke P C Hazenberg; Arnt V Kristen; Raymond Y Kwong; Mathew S Maurer; Giampaolo Merlini; Edward J Miller; James C Moon; Venkatesh L Murthy; C Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Sanjiv J Shah; Riemer H J A Slart; Hein J Verberne; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2019-12       Impact factor: 5.952

3.  State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis.

Authors:  Vasvi Singh; Rodney Falk; Marcelo F Di Carli; Marie Kijewski; Claudio Rapezzi; Sharmila Dorbala
Journal:  J Nucl Cardiol       Date:  2018-12-19       Impact factor: 5.952

Review 4.  Targeted Nuclear Imaging Probes for Cardiac Amyloidosis.

Authors:  Paco E Bravo; Sharmila Dorbala
Journal:  Curr Cardiol Rep       Date:  2017-07       Impact factor: 2.931

5.  Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy.

Authors:  Youssef Bennani Smires; Gérard Victor; David Ribes; Matthieu Berry; Thomas Cognet; Simon Méjean; Antoine Huart; Murielle Roussel; Antoine Petermann; Jérôme Roncalli; Didier Carrié; Hervé Rousseau; Isabelle Berry; Dominique Chauveau; Michel Galinier; Olivier Lairez
Journal:  Int J Cardiovasc Imaging       Date:  2016-05-30       Impact factor: 2.357

6.  Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.

Authors:  Sajitha Sachchithanantham; Mark Offer; Christopher Venner; Shameem A Mahmood; Darren Foard; Lisa Rannigan; Thirusha Lane; Julian D Gillmore; Helen J Lachmann; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

7.  99mTc-DPD-scintigraphy with intense uptake in fat tissue caused by AL-amyloidosis.

Authors:  M Zoller; G Hajnos; R Burkhard; S Kneifel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-28       Impact factor: 9.236

8.  Liver dysfunction as predictor of prognosis in patients with amyloidosis: utility of the Model for End-stage Liver disease (MELD) scoring system.

Authors:  Francesco Cappelli; Samuele Baldasseroni; Franco Bergesio; Valentina Spini; Alessia Fabbri; Paola Angelotti; Elisa Grifoni; Paola Attanà; Francesca Tarantini; Niccolò Marchionni; Alberto Moggi Pignone; Federico Perfetto
Journal:  Intern Emerg Med       Date:  2016-08-01       Impact factor: 3.397

Review 9.  Cardiac amyloidosis: the great pretender.

Authors:  Claudio Rapezzi; Massimiliano Lorenzini; Simone Longhi; Agnese Milandri; Christian Gagliardi; Ilaria Bartolomei; Fabrizio Salvi; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

10.  Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers.

Authors:  Eve Piekarski; Renata Chequer; Vincent Algalarrondo; Ludivine Eliahou; Besma Mahida; Jonathan Vigne; David Adams; Michel S Slama; Dominique Le Guludec; Francois Rouzet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-06       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.